Application of artificial intelligence techniques for non-alcoholic fatty liver disease diagnosis: A systematic review (2005-2023)
- PMID: 38008040
- DOI: 10.1016/j.cmpb.2023.107932
Application of artificial intelligence techniques for non-alcoholic fatty liver disease diagnosis: A systematic review (2005-2023)
Abstract
Background and objectives: Non-alcoholic fatty liver disease (NAFLD) is a common liver disease with a rapidly growing incidence worldwide. For prognostication and therapeutic decisions, it is important to distinguish the pathological stages of NAFLD: steatosis, steatohepatitis, and liver fibrosis, which are definitively diagnosed on invasive biopsy. Non-invasive ultrasound (US) imaging, including US elastography technique, and clinical parameters can be used to diagnose and grade NAFLD and its complications. Artificial intelligence (AI) is increasingly being harnessed for developing NAFLD diagnostic models based on clinical, biomarker, or imaging data. In this work, we systemically reviewed the literature for AI-enabled NAFLD diagnostic models based on US (including elastography) and clinical (including serological) data.
Methods: We performed a comprehensive search on Google Scholar, Scopus, and PubMed search engines for articles published between January 2005 and June 2023 related to AI models for NAFLD diagnosis based on US and/or clinical parameters using the following search terms: "non-alcoholic fatty liver disease", "non-alcoholic steatohepatitis", "deep learning", "machine learning", "artificial intelligence", "ultrasound imaging", "sonography", "clinical information".
Results: We reviewed 64 published models that used either US (including elastography) or clinical data input to detect the presence of NAFLD, non-alcoholic steatohepatitis, and/or fibrosis, and in some cases, the severity of steatosis, inflammation, and/or fibrosis as well. The performances of the published models were summarized, and stratified by data input and algorithms used, which could be broadly divided into machine and deep learning approaches.
Conclusion: AI models based on US imaging and clinical data can reliably detect NAFLD and its complications, thereby reducing diagnostic costs and the need for invasive liver biopsy. The models offer advantages of efficiency, accuracy, and accessibility, and serve as virtual assistants for specialists to accelerate disease diagnosis and reduce treatment costs for patients and healthcare systems.
Keywords: Artificial intelligence; Deep learning; Diagnosis; Fatty liver; Healthcare; Machine learning; NAFLD; NASH.
Copyright © 2023. Published by Elsevier B.V.
Conflict of interest statement
Declaration of Competing Interest The authors declare that they have no conflicts in financial interests or personal relationships that can influence the work reported in this paper.
Similar articles
-
Ultrasonography for diagnosis of alcoholic cirrhosis in people with alcoholic liver disease.Cochrane Database Syst Rev. 2016 Mar 2;3(3):CD011602. doi: 10.1002/14651858.CD011602.pub2. Cochrane Database Syst Rev. 2016. PMID: 26934429 Free PMC article.
-
Applications of artificial intelligence (AI) in researches on non-alcoholic fatty liver disease(NAFLD) : A systematic review.Rev Endocr Metab Disord. 2022 Jun;23(3):387-400. doi: 10.1007/s11154-021-09681-x. Epub 2021 Aug 15. Rev Endocr Metab Disord. 2022. PMID: 34396467
-
Artificial intelligence for detecting keratoconus.Cochrane Database Syst Rev. 2023 Nov 15;11(11):CD014911. doi: 10.1002/14651858.CD014911.pub2. Cochrane Database Syst Rev. 2023. PMID: 37965960 Free PMC article.
-
The Prevalence of Small Intestinal Bacterial Overgrowth in Patients with Non-Alcoholic Liver Diseases: NAFLD, NASH, Fibrosis, Cirrhosis-A Systematic Review, Meta-Analysis and Meta-Regression.Nutrients. 2022 Dec 9;14(24):5261. doi: 10.3390/nu14245261. Nutrients. 2022. PMID: 36558421 Free PMC article.
-
Insulin sensitisers in the treatment of non-alcoholic fatty liver disease: a systematic review.Health Technol Assess. 2011 Nov;15(38):1-110. doi: 10.3310/hta15380. Health Technol Assess. 2011. PMID: 22059955 Free PMC article.
Cited by
-
Advancements in Artificial Intelligence-Enhanced Imaging Diagnostics for the Management of Liver Disease-Applications and Challenges in Personalized Care.Bioengineering (Basel). 2024 Dec 9;11(12):1243. doi: 10.3390/bioengineering11121243. Bioengineering (Basel). 2024. PMID: 39768061 Free PMC article. Review.
-
FF Swin-Unet: a strategy for automated segmentation and severity scoring of NAFLD.BMC Med Imaging. 2025 Jul 10;25(1):278. doi: 10.1186/s12880-025-01805-y. BMC Med Imaging. 2025. PMID: 40640704 Free PMC article.
-
The current status and future directions of artificial intelligence in the prediction, diagnosis, and treatment of liver diseases.Digit Health. 2025 Apr 13;11:20552076251325418. doi: 10.1177/20552076251325418. eCollection 2025 Jan-Dec. Digit Health. 2025. PMID: 40290269 Free PMC article. Review.
-
Machine learning-based identification of biochemical markers to predict hepatic steatosis in patients at high metabolic risk.World J Gastroenterol. 2025 Jul 21;31(27):108200. doi: 10.3748/wjg.v31.i27.108200. World J Gastroenterol. 2025. PMID: 40741101 Free PMC article.
-
Diagnostic accuracy of convolutional neural networks in classifying hepatic steatosis from B-mode ultrasound images: a systematic review with meta-analysis and novel validation in a community setting in Telangana, India.Lancet Reg Health Southeast Asia. 2025 Jul 31;40:100644. doi: 10.1016/j.lansea.2025.100644. eCollection 2025 Sep. Lancet Reg Health Southeast Asia. 2025. PMID: 40791854 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical